A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt V, Harter P. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 2009; 21:370-5.
04.11.2009
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
04.11.2009
Ann Oncol 2009; 21:370-5
du Bois A, Huober Jens, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt V L, Harter P
Weiter
